Accendra Health, Inc. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Next earnings (estimated): Wed, April 1, 2026 — 28 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $709M | — | — | — | 0.1% |
| 2025-09-30 | $697M | ↑+1.5% | $-150M | ↓-1076.8% | 3.8% |
| 2025-06-30 | $682M | ↑+3.3% | $-869M | ↓-2623.2% | -5.8% |
| 2025-03-31 | $2.63B | ↑+0.7% | $-25M | ↓-14.1% | 0.0% |
| 2024-12-31 | — | — | — | — | — |
| 2024-09-30 | $687M | ↓-73.5% | $-13M | ↓-98.7% | 4.5% |
| 2024-06-30 | $660M | ↓-74.2% | $-32M | ↓-13.0% | 2.6% |
| 2024-03-31 | $2.61B | ↑+3.6% | $-22M | ↑+10.4% | 0.4% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Revenue
$709M
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 67 quarters
margin trajectory tells the operating-leverage storyGross Margin↓-0.5pts
20.0%
Operating Margin
0.1%
Net Margin↓-19.7pts
-21.6%
Go deeper
ACH Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyACH Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics